Key Highlights

  • Pacific Biosciences of California (NASDAQ:PACB) fell 5.9% to USD 2.70 on October 6, 2026, with genomics peers also weak and no company news explaining the move.
  • Second-quarter Revenue was USD 39.0 million, flat from USD 39.8 million a year earlier, with a GAAP net loss of USD 44.7 million, per the company release.
  • Pacific Biosciences (NASDAQ:PACB) ended June with USD 236.9 million of cash and investments, down from USD 314.7 million a year earlier, against USD 644.3 million of convertible notes.
  • Management guides 2026 revenue to USD 155 million to USD 165 million, and Mark Van Oene became president and chief executive on August 5, 2026.

A 5.9% Drop With No Company Trigger

Published market data showed Pacific Biosciences of California (NASDAQ:PACB) falling 5.9% to USD 2.70 on October 6, 2026. The move came alongside weakness in other genomics and biotech names, including Guardant Health and Caribou Biosciences, which points to sector pressure rather than a company event. We found no PacBio release or filing dated October 5 or 6, so the cause is unverified. At that price, using the second-quarter weighted average of 310.4 million basic shares, simple arithmetic suggests an Equity value near USD 840 million, though the current share count may differ. Falls of this size are common for sequencing-tools names when sentiment toward research funding or rates changes.

What the Second Quarter Showed

PacBio reported second-quarter 2026 results on August 5. Revenue of USD 39.0 million was flat with USD 39.8 million a year earlier, and the GAAP net loss widened to USD 44.7 million from USD 41.9 million, or 14 cents a share. GAAP gross Margin fell to 32% from 37%, which the company blamed on higher compute and memory costs, Vega Manufacturing transition costs and lower Revio selling prices. It placed 20 Revio and 26 Vega systems. The SPRQ-Nx chemistry launched with a whole genome list price of USD 345. A restructuring aims to streamline Marketing and research and development. Operating expenses were USD 57.2 million, below USD 59.5 million a year earlier.

Cash, Debt and Dates Ahead

Cash, equivalents and investments were USD 236.9 million on June 30, 2026, against convertible senior notes of USD 644.3 million on the balance sheet. Simple arithmetic on those two figures gives net debt of about USD 407 million. The company did not give a cash runway or note maturities in the release we reviewed, so both are unverified. Revenue guidance of USD 155 million to USD 165 million implies a heavier second half than the first. Risks include margin pressure, a new chief executive, slow instrument Demand and refinancing the notes. The third-quarter report date has not been announced; the second-quarter call was held at 4:30 p.m. ET on August 5.

Where Things Stand

Pacific Biosciences of California (NASDAQ:PACB) fell 5.9% to USD 2.70 on October 6, 2026 probably because genomics names weakened together, since the company reported nothing new. Fundamentals are mixed: flat revenue, a 32% gross margin and a USD 44.7 million quarterly loss, offset by new chemistry and a new chief executive. Cash of USD 236.9 million against USD 644.3 million of convertible notes is the central issue. Watch for the third-quarter report date, margin recovery and any Capital or restructuring announcements.